UOTTAIMCU
REGN icon

University of Texas/Texas AM Investment Management Co (UTIMCO)’s Regeneron Pharmaceuticals REGN Stock Holding History

University of Texas/Texas AM Investment Management Co (UTIMCO)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.8K Buy
+59
New +$40.2K ﹤0.01% 319

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO)'s REGN Position: Q2 2026 in Review

University of Texas/Texas AM Investment Management Co (UTIMCO) opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 59 shares worth $36.8K. The stake represents ﹤0.01% of the portfolio and ranks #319 among its holdings.

987 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • University of Texas/Texas AM Investment Management Co (UTIMCO) held 59 shares of Regeneron Pharmaceuticals worth $36.8K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new University of Texas/Texas AM Investment Management Co (UTIMCO) position in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of University of Texas/Texas AM Investment Management Co (UTIMCO)'s portfolio in Q2 2026, its #319 holding.
  • 987 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q2 2026, filed 3 Aug 2026.